New asthma drug shows promise in early human trials
NCT ID NCT07245368
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study tests a new drug called PRA-216 in two phases. First, healthy volunteers receive single or multiple doses to check safety. Then, people with mild-to-moderate asthma receive the drug to see if it reduces airway inflammation and improves asthma control. The goal is to find a safe and effective treatment for asthma symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD TO MODERATE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Emeritus Research Camberwell
RECRUITINGCamberwell, Victoria, 3124, Australia
-
Emertitus Research Sydney
RECRUITINGBotany, New South Wales, 2019, Australia
-
Linear
RECRUITINGJoondalup, Western Australia, 6027, Australia
Contact Email: •••••@•••••
-
Linear
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Email: •••••@•••••
-
Monash Health
NOT_YET_RECRUITINGClayton, Victoria, 3168, Australia
-
PCRN Waikato, Nawton
RECRUITINGHamilton, Auckland, 3200, New Zealand
Contact Email: •••••@•••••
-
PCRN Wellington, Ebdentown
RECRUITINGUpper Hutt, Auckland, 5018, New Zealand
Contact Email: •••••@•••••
-
Pacific Clinical Research Network-Auckland
RECRUITINGTakapuna, Auckland, 0622, New Zealand
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.